Taiwan and Australia Build a Fast Track for Clinical Trials: How Taiwan’s Biotech Sector Can Leverage It to Go Global

For a new drug moving from the laboratory to the international market, the points most likely to cause it to lose momentum are often not the scientific concept, but clinical trial initiation, participant recruitment, and the alignment of multinational regulatory requirements. Taiwan and Australia are trying to connect these stages: enabling Taiwanese biotech companies to use Australia’s early-stage clinical environment to obtain human data, then advance late-stage, multiregional trials from Taiwan or other markets.

The “Australia–Taiwan Clinical Trials and Bio Innovation Forum,” held on July 15 at Taipei Nangang Exhibition Center, Hall 2, was jointly organized by the Australian Office, the Biotechnology and Pharmaceutical Industries Promotion Office of the Ministry of Economic Affairs, and the Taiwan Bio Industry Organization. The organizers said the event brought together 27 Australian clinical trial service providers and three biotech companies, spanning contract research organizations, trial sites, bioanalytical laboratories, clinical logistics, and patient recruitment technologies, and included one-on-one meetings between Taiwanese and Australian companies.

Australia’s main attraction is that trials of certain unapproved therapeutic goods can use the Clinical Trial Notification scheme (CTN). Under this pathway, Australia’s Therapeutic Goods Administration does not review all trial materials on a case-by-case basis at the time of notification; scientific and ethical assessments are primarily the responsibility of Human Research Ethics Committees and the institutions conducting the trials. Once ethics, institutional, notification, and other requirements are completed, a trial may begin without separately following a US-style public IND process. This does not mean that review is waived. High-risk products may still need to follow the Clinical Trial Approval scheme (CTA), and all trials must comply with ethical, institutional, and Good Clinical Practice requirements.

Cost is another important pillar of this bridge. The Australian delegation introduced R&D tax incentives to Taiwanese companies. Eligible businesses with annual turnover below the threshold may receive a refundable tax offset calculated at the corporate tax rate plus 18.5 percentage points, equivalent to a maximum of 43.5% under certain tax-rate conditions. However, the incentive depends on corporate structure and the eligibility of R&D activities and expenditures, and cannot be directly regarded as a refund at the same rate for every clinical trial.

The capabilities of service providers participating in the forum spanned first-in-human trials, Phase I through Phase III studies, bioanalysis, cold-chain logistics, and artificial intelligence-assisted patient matching. Avance Clinical presented a model that uses its existing Taiwan operations to connect with early-stage trials in Australia and then support late-stage development in North America and other regions. The company said data generated through the Australian pathway can be used in submissions to regulators in the United States, Europe, Australia, and the United Kingdom. Whether such data will be accepted, however, still depends on the individual product, trial design, data quality, and local regulatory requirements. Completing an Australian trial does not automatically provide a global passport.

The event indicates that Taiwan–Australia cooperation has moved beyond general industry exchanges to focus more closely on executable divisions of trial responsibilities and supply-chain connections. However, the information currently available to the public consists mainly of the forum agenda, participant list, and service models proposed by companies. No newly signed clinical collaborations, evidence of shortened timelines, or comparative cost-saving data have yet been disclosed. Whether this clinical bridge will genuinely accelerate Taiwanese new drugs’ path to global markets will have to be answered by the trials subsequently initiated, the results of multinational regulatory submissions, and the actual scale of cooperation.